Smouldering multiple myeloma (SMM) is a plasma cell disorder that is asymptomatic and considered pre-malignant, with risks of progression to myeloma.

Diagnosis follows the 2014 IMWG criteria, requiring specific monoclonal protein levels and plasma cell percentages.

It is essential to rule out organ damage and malignancy biomarkers. SMM is often found incidentally during routine check-ups, and while tests are accessible in urban areas, challenges remain in remote locations.